Gregory Lacek
Medical · Uniontown, PANPI 1730182056
Payments from drug & device makers
Across 982 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$1K
- Pfizer$1K
- GSK$1K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- plus $8K from 46 others
What the payments were for
- Food & beverage$15,714100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,726 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 261 | $184,224 |
| OzempicSemaglutide | 136 | $173,745 |
| XareltoRivaroxaban | 137 | $118,240 |
| TrulicityDulaglutide | 78 | $99,166 |
| MounjaroTirzepatide | 70 | $85,530 |
| JanuviaSitagliptin Phosphate | 67 | $53,450 |
| Ambrisentan | 11 | $50,366 |
| TradjentaLinagliptin | 60 | $49,259 |
| JardianceEmpagliflozin | 49 | $45,748 |
| Humulin R U-500Insulin Regular, Human | 13 | $37,383 |
| LinzessLinaclotide | 43 | $32,533 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $26,259 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $26,254 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $23,143 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $18,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,761 | $188,991152 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,076 | $184,695148 claims |
| PfizerEliquis | $1,260 | $184,224261 claims |
| Johnson & JohnsonXarelto | $777 | $118,240137 claims |
| Boehringer IngelheimTradjenta, Jardiance, Stiolto Respimat | $997 | $104,530130 claims |
| MerckJanuvia | $126 | $53,45067 claims |
| AbbVieLinzess, Restasis | $1,481 | $39,72554 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,161 | $38,98755 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $1,117 | $36,72854 claims |
| Astellas Pharma US IncMyrbetriq | $186 | $16,00735 claims |
| BayerKerendia | $574 | $8,19213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Uniontown
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.